Ro weight loss and Hims weight loss are the two largest GLP-1-focused men’s and women’s telehealth programs from broadly DTC platforms. Both have grown explosively since the GLP-1 boom of 2022-2023, both have pivoted significantly with the 2025 changes to the FDA semaglutide and tirzepatide shortage list, and both now operate primarily through branded GLP-1 medication delivery with limited compounded options. This ro weight loss vs hims weight loss comparison breaks down 2026 pricing, clinical models, medication access, and which platform delivers better value. The summary: Hims has historically been more aggressive on promotional pricing; Ro has slightly cleaner program structure. The differences are smaller than the marketing suggests.
Ro vs Hims weight loss — pricing in 2026
Ro Body weight loss program:
- Initial visit: $99
- Monthly membership: $145/month (separate from medication)
- Compounded GLP-1s when available: $250-450/month historically
- Branded Wegovy/Zepbound: ~$1,000+/month without insurance, lower with coverage
- Includes: clinician evaluation, ongoing care, lab work review, prescription management
Hims weight loss program:
- Initial visit: $79
- Monthly cost: $99-199/month for ongoing care, plus medication
- Compounded GLP-1s: previously $199-299/month, mostly phased out by 2025
- Branded Wegovy/Zepbound: ~$1,000+/month without insurance
- Promotional pricing often available at signup
The pricing gap between the two programs is small at the visit and membership level. Medication pricing is similar for branded GLP-1s (both at manufacturer-set rates) and was historically similar for compounded options where available. See our individual Ro review and Hims review.
What changed with the 2025 FDA shortage list updates
Through 2024, both Ro and Hims aggressively marketed compounded semaglutide at $199-299 per month, drawing significant patient volume into their weight loss programs. The compounded medications were legal under FDA rules during the shortage period.
The FDA’s 2025 decisions removing semaglutide from the shortage list (and similar decisions on tirzepatide) forced both platforms to phase out most compounded options. As of 2026, both Ro and Hims primarily prescribe branded Wegovy and Zepbound for new patients, with limited compounded options remaining for specific clinical scenarios.
This shift fundamentally changes the value proposition of both platforms. The “low-cost compounded GLP-1 access” that drove growth in 2024 is largely gone. Both platforms now compete primarily on branded medication delivery, where pricing is set by manufacturers rather than the platforms.
Clinical model — both similar
Both platforms use a similar clinical model: video-based initial evaluation with a clinician, eligibility screening based on FDA labeling (BMI 27+ with comorbidity or 30+ without), contraindication assessment including personal or family history of medullary thyroid carcinoma per FDA guidance, and ongoing monthly check-ins for prescription management.
The clinical depth at both platforms is reasonable but not exceptional. Calibrate offers more intensive structured coaching, and Found offers more comprehensive clinical assessment with broader medication formulary. Ro and Hims occupy a middle position — competent medical management with minimal wraparound coaching.
Medication delivery and pharmacy partnerships
Both platforms operate or partner with pharmacies that ship GLP-1 medications directly to patients. Ro Pharmacy is operated by Ro itself; Hims partners with affiliated pharmacies for distribution.
For branded Wegovy and Zepbound, pricing is set by the manufacturers (Novo Nordisk and Eli Lilly respectively). Both platforms can coordinate with manufacturer savings programs and discount cards to reduce out-of-pocket cost for eligible patients. The platforms can also coordinate with patient insurance for branded medications when coverage applies.
Insurance coordination
Neither platform bills insurance for the program fee or visit. Both can coordinate prescriptions with patient insurance for branded GLP-1 medications, which is where most of the medication cost lives. The insurance navigation experience is broadly similar at both platforms — neither does the work for the patient, but both provide guidance on prior authorization and coverage.
For patients with strong GLP-1 insurance coverage, both platforms produce similar total costs since the medication insurance handling is the primary cost factor. For patients without coverage, both platforms have similar limitations — branded GLP-1s clear $1,000+/month at retail.
Customer experience and complaints
Both platforms have documented customer service complaints around auto-renewal billing, cancellation difficulty, and shipping delays for compounded medications during the 2024-2025 transition period. The complaint volume is similar in absolute terms.
Hims has been a slightly more aggressive marketer with stronger promotional pricing, which produces more first-time signups and proportionally more billing-related complaints. Ro’s experience tends to be slightly more professional in tone and structure but produces similar complaint patterns at scale. Patients should set calendar reminders before quarterly shipments and verify cancellation has been processed when ending subscriptions.
Specific use cases — when each platform wins
Choose Ro if: You prefer slightly cleaner program structure with the $145 monthly membership clearly separated from medication costs. You’re already using Ro for other men’s health needs (hair loss, ED) and want to consolidate.
Choose Hims if: Hims is running aggressive promotional pricing at the time of signup that makes it cheaper than Ro. You’re already using Hims for other needs (hair loss, ED, mental health) and want consolidation. You’re a woman seeking weight loss (the parallel Hers brand uses the same infrastructure).
Choose neither if: You want intensive structured coaching beyond what either platform offers. Calibrate and Found provide more clinical depth and coaching support. Calibrate vs Found covers the more clinically focused alternatives.
How both compare to Calibrate, Found, and Noom Med
Compared to Calibrate, both Ro and Hims are cheaper at the program level but offer minimal coaching versus Calibrate’s intensive weekly sessions. Compared to Found, both Ro and Hims have narrower medication formularies (GLP-1-focused) versus Found’s broader options. Compared to Noom Med, both Ro and Hims have lighter behavioral content but more streamlined clinical pathways. See Wegovy through Hims vs Ro for the branded medication-focused comparison.
Frequently Asked Questions
Which is cheaper, Ro or Hims weight loss?
Pricing is comparable. Hims has historically run more aggressive promotional pricing on the visit fee ($79 vs $99). Ro’s monthly membership is $145; Hims’s monthly cost is $99-199 depending on plan. Total cost depends primarily on medication choice.
Do both prescribe Wegovy?
Yes. Both Ro and Hims prescribe FDA-approved GLP-1 medications including Wegovy and Zepbound for eligible patients. Compounded options are limited as of 2026 due to FDA shortage list updates.
Does either accept insurance?
Neither bills insurance for the visit or program fee. Both coordinate prescriptions for branded GLP-1 medications where insurance can apply to the medication itself.
Which has better coaching?
Neither offers intensive coaching. Both provide ongoing clinician check-ins. For substantial coaching support, Calibrate is the stronger choice.
Are GLP-1 prescriptions through Ro or Hims legitimate?
Yes. Both platforms use licensed clinicians, FDA-approved medications, and FDA-registered partner pharmacies. Branded Wegovy and Zepbound delivered through these platforms are the same products dispensed at retail pharmacies.
The bottom line on Ro weight loss vs Hims weight loss
Ro and Hims weight loss programs are more similar than different in 2026. Both deliver branded GLP-1 medications with reasonable clinical infrastructure, similar pricing, and comparable customer experiences. Hims has historically run more aggressive promotional pricing; Ro has slightly cleaner program structure. The 2025 FDA shortage list updates fundamentally changed both platforms by phasing out most compounded options, leaving both competing primarily on branded medication delivery. For patients seeking medical weight loss with minimal coaching, either works. For patients wanting more clinical depth or behavioral support, Calibrate or Found are stronger alternatives.